Why the drug development pipeline is not delivering better medicines
File(s)bmj.h5542.full.pdf (1.05 MB)
Published version
OA Location
Author(s)
Naci, H
Carter, AW
Mossialos, E
Type
Journal Article
Abstract
Despite the large number of new medicines entering the market every year, few offer important
clinical advantages for patients. Huseyin Naci, Alexander Carter, and Elias Mossialos explain
the reasons for this innovation deficit and offer some solutions
clinical advantages for patients. Huseyin Naci, Alexander Carter, and Elias Mossialos explain
the reasons for this innovation deficit and offer some solutions
Date Issued
2015-10-23
Date Acceptance
2015-10-08
Citation
BMJ-BRITISH MEDICAL JOURNAL, 2015, 351 (2015)
ISSN
1756-1833
Publisher
BMJ PUBLISHING GROUP
Journal / Book Title
BMJ-BRITISH MEDICAL JOURNAL
Volume
351
Issue
2015
Copyright Statement
© 2015 BMJ Publishing Group Ltd
Identifier
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000364146900001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
Subjects
Science & Technology
Life Sciences & Biomedicine
Medicine, General & Internal
General & Internal Medicine
RESEARCH-AND-DEVELOPMENT
PHARMACEUTICAL-INDUSTRY
INNOVATION
EFFICACY
COST
SAFETY
FDA
LEGISLATION
DECISIONS
PROMOTION
Costs and Cost Analysis
Drug Approval
Drug Industry
Drug and Narcotic Control
Europe
Government Regulation
Humans
Marketing of Health Services
Medication Therapy Management
United States
Publication Status
Published
Article Number
ARTN h5542